profit from every A$100 of sales.
A$0A$100
Ansell
A$45.76+0.22% today
+25.2% in 1 year
1-year low A$25.051-year high A$46.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay A$43.91 for every A$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ansell sold, what it kept, and what it did with the cash.
Sales went from $1.95 billion in 2022 to $2.00 billion in 2025, with $102 million of profit last year.
SalesProfit
Ansell handed back 40% of the cash it generated last year.
$64M
Free cash flow 2025$170M
Bought back its own shares$4M
Paid as dividends$64M
Cash vs. debt$238M vs. $806M
Ansell vs. similar companies
Ansell grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from A$100 of sales | Sales growth a year | Price per A$1 of profit |
|---|---|---|---|
| Ansell | 43.9× · Expensive | ||
 Intuitive Surgical | 55.9× · Expensive | ||
 EssilorLuxottica Société anonyme | 37.7× · Expensive | ||
 Becton, Dickinson and | 34.9× · Expensive | ||
 Medline | 46.2× · Expensive |
AI analysis
An AI analyst reads Ansell's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,952 | 1,655 | 1,619 | 2,003 | |
| 666 | 617 | 625 | 825 | |
| 171 | 140 | 57 | 109 | |
| 292 | 275 | 202 | 260 | |
| 159 | 148 | 77 | 102 | |
| 1.24 | 1.17 | 0.59 | 0.70 | |
| 34.1% | 37.3% | 38.6% | 41.2% | |
| 8.8% | 8.4% | 3.5% | 5.4% | |
| 8.1% | 9.0% | 4.7% | 5.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,506 | 2,531 | 3,243 | 3,322 |
| Cash | 206 | 159 | 912 | 238 |
| Total debt | 486 | 494 | 857 | 806 |
| Total liabilities | 950 | 915 | 1,332 | 1,340 |
| 1,543 | 1,601 | 1,895 | 1,964 | |
| 128 | 127 | 129 | 146 | |
| 7.8% | 6.9% | 3.3% | 4.7% | |
| 10.3% | 9.3% | 4.0% | 5.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 68 | 67 | 63 | 69 | |
| 155 | 113 | 210 | 170 | |
| Dividends paid | 87 | 63 | 53 | 64 |
| 49 | 8 | 30 | 4 | |
| – | – | – | – |
Valuation
- 43.9×
- –
- –
- 2.1×
- 2.2×
- 26.2×
- 19.3×
- 3.8%
- 2.3%
- 1.4%
Profitability
- 41.2%
- 5.4%
- 5.1%
- –
- 4.7%
- 5.7%
- –
- –
- –
- –
Growth
- +0.9%
- −17.5%
- –
- –
- +4.5%
Financial health
- 2.2×
- 0.41
- –
- 4.5×
- 2.13
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 48%of 948
Bottom 41%of 871
Bottom 28%of 560
Bottom 18%of 868
Top 28%of 985
1.4%of the share price, paid each year
On $1,000 invested$14a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
62.7% of its profit
Room to growStretchedMore than it earns: 37.5%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
48No pass
Philip Fisher
20No pass
Peter Lynch
20No pass
Joel Greenblatt
8No pass
Charlie Munger
23No pass
Terry Smith
30No pass
Questions about Ansell
Is Ansell a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ansell AI analysis
What does Ansell do?
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial. It is in Medical Instruments & Supplies, based in Richmond, VIC, Australia, with 15,000 employees.
Does Ansell pay a dividend?
Yes. At today's price the dividend is 1.4% a year, about 63% of its yearly profit. In 2025 it paid out A$63.7 million in dividends.
Is Ansell stock halal?
Yes. Ansell passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Ansell stock done over the past year?
Up 25.2% over the past twelve months, to A$45.76. It traded between A$25.05 and A$46.50, close to its high.
Who are Ansell's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Ansell's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.